Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial
Abstract Background Transarterial chemoembolization (TACE) is commonly used to treat patients with unresectable hepatocellular carcinoma (HCC); however, TACE alone has demonstrated unsatisfactory survival benefits. Our previous studies suggested that TACE plus oral medication of thalidomide, carmofu...
Saved in:
| Main Authors: | Jie Li, Bei Lv, Li Song, Xingxing Zhang, Jian Zhang, Xiaoyi Ding, Yongqiang Liu, Tao Ye, Mengzhou Guo, Tingting Fang, Biwei Yang, Zhiying Zhao, Peixin Huang, Yi Chen, Ningling Ge, Jinglin Xia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06624-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01) -
Comparative Effectiveness and Safety of Molecular Targeted Therapy Plus PD-(L)1 with or without TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Study
by: Liu J, et al.
Published: (2025-07-01) -
TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study
by: Lu C, et al.
Published: (2025-07-01) -
Efficacy Analysis of TACE Combined with Lenvatinib and PD-1 Inhibitors in the Treatment of Hepatitis B Virus-Related Unresectable Hepatocellular Carcinoma
by: Yu J, et al.
Published: (2025-07-01) -
Application of Nanotechnology in TACE Treatment of Liver Cancer
by: Yao L, et al.
Published: (2025-08-01)